Media Release

Syngenta AG Rosentalstrasse 67 4002 Basel, Switzerland Boston, MA 02210, USA www.syngenta.com

Ginkgo Bioworks 27 Drydock Avenue, 8th Floor www.ginkgobioworks.com

Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals

Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution

Basel, Switzerland and Boston, MA. USA, 16 Jul 2024 - Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology.

Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can meet the productivity targets of a secondary metabolite from the Syngenta Biologicals pipeline. This molecule is earmarked by Syngenta as a pioneering biological solution. Successful cost-effective and large-scale production of this targeted metabolite would significantly expedite Syngenta's go-to-market timeline for its latest biological solution.

To achieve this, Ginkgo will use its Ag Biologicals capabilities to calculate theoretical performance and guide rational strain engineering strategies to develop the microbial strain that is robust enough to meet Syngenta's goals. Ginkgo will leverage its biological knowledge and machine learning approaches to develop insights from multiple complex data sources and apply this toward diagnosing strain performance limitations as well as biological feature discovery.

"Biologicals are increasingly important in addressing the need for efficient and sustainable agricultural solutions worldwide. At Syngenta, we are committed to providing farmers with greater complementary product and technology choices that promote sustainable agricultural practices," said Camilla Corsi, Global Head of Research at Syngenta Crop Protection. "We are





excited to work with Ginkgo, and are confident that their distinctive capabilities will enable us to achieve our productivity goals for our targeted molecule, expediting our time to market."

Magalie Guilhabert, Head of Ag Biologicals at Ginkgo Bioworks, said: "We are so excited to expand our relationship with Syngenta. We've built a successful relationship from our work together on plant traits and now look forward to doing the same with ag biologicals. Ginkgo is proud to put our excellent assets and experience against some of our customer's toughest challenges. We'll work to achieve productivity levels to realize commercial viability for Syngenta's innovative ag biologicals product launch."

About Syngenta Crop Protection



Syngenta Crop Protection is a leader in agricultural innovation, bringing breakthrough technologies and solutions that enable farmers to grow productively and sustainably. We offer a leading portfolio of crop protection solutions for plant and soil health, as well as digital solutions that transform the decision-making capabilities of farmers. Our 18,300 employees serve to advance agriculture in more than 90 countries around the world. Syngenta Crop Protection is headquartered in Basel, Switzerland, and is part of the Syngenta Group. Follow us on X (@Syngenta, @SyngentaUS), and on LinkedIn.

Contact Information media@syngentagroup.com



About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

To learn more about Ginkgo's Ag Biologicals capabilities, please visit: <u>https://www.ginkgobioworks.com/offerings/ag-biologicals-discovery-</u> <u>development/#production-strain-engineering</u>

Gingko Bioworks Investor & Media contacts investors@ginkgobioworks.com press@ginkgobioworks.com

Syngenta's Cautionary Statement Regarding Forward-Looking Statements

This document may contain forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

©2024 Syngenta. Rosentalstrasse 67, 4058 Basel, Switzerland.

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on May 9, 2024 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.